Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prosensa names new supervisory board member

This article was originally published in Scrip

Executive Summary

Dutch biopharmaceutical company Prosensa, which is developing therapies to treat rare diseases, has named Michael S Wyzga to its supervisory board – effective from its next meeting of shareholders on 17 June 2014. Mr Wyzga most recently served as president and chief executive officer of Radius Health. Prior to joining Radius, he was executive vice-president and chief financial officer of Genzyme (prior to its acquisition by Sanofi in April 2011). Mr Wyzga currently serves on the board of directors for OncoMed Pharmaceuticals, Akebia Therapeutics and Idenix Pharmaceuticals.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC024995

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel